Pharmacological or genetic inhibition of the RON receptor resulted in attenuated AKT and MAPK signaling and reduced cell growth in vitro, whereas manipulation of the pathway significantly improved survival and delayed tumor growth in vivo. The gene discussed is AKT1; the disease is neoplasm.